您当前所在的位置:首页 > 产品中心 > 产品信息
Aprepitant_分子结构_CAS_170729-80-3)
点击图片或这里关闭

Aprepitant

产品号 DB00673 公司名称 DrugBank
CAS号 170729-80-3 公司网站 http://www.ualberta.ca/
分子式 C23H21F7N4O3 电 话 (780) 492-3111
分子量 534.4266624 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 555

产品价格信息

请登录

产品别名

标题
Aprepitant
IUPAC标准名
5-{[(2S,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,3-dihydro-1H-1,2,4-triazol-3-one
IUPAC传统名
emend
商标名
Emend
别名
MK-869
MK-0517
aprepitant

产品登记号

CAS号 170729-80-3

产品性质

疏水性(logP) 4.5
溶解度 Practically insoluble

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved; investigational
Description Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).
Indication For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents).
Pharmacology Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).
Affected Organisms
Humans and other mammals
Biotransformation Aprepitant is metabolized primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19. Seven metabolites of aprepitant, which are only weakly active, have been identified in human plasma.
Absorption The mean absolute oral bioavailability of aprepitant is approximately 60 to 65%.
Half Life 9-13 hours
Protein Binding >95%
Elimination Aprepitant is eliminated primarily by metabolism; aprepitant is not renally excreted. Aprepitant is excreted in the milk of rats. It is not known whether this drug is excreted in human milk.
Distribution * 70 L
Clearance * Apparent plasma cl=62-90 mL/min
External Links
Wikipedia
RxList
Drugs.com

参考文献